natgillin/translations-raw huggingface dataset:
At least a portion of the sealing material can be partially compressed by the enclosing members when closing the capsule enclosure space. 
Najmanje jedan dio materijala za brtvljenje može biti djelomično stisnut elementima koji obuhvaćaju čahuru kada se čahura zatvara u prostor koji je obuhvaća kada je zatvorena.
Also disclosed is the use of the polypeptide for the preparation of a pharmaceutical composition for treating a subject that has suffered a dorsal root nerve injury. 
Polipeptid za uporabu kao u zahtjevu 27, naznačen time, što polipeptid treba primjeniti kod subjekta u okviru 48 sati od povrede živca dorzalnog korjena.
The bed arrangement of claim 2, wherein the at least two zones, including at least one of firmness and height which is independently adjustable, extend over essentially the whole width of the mattress, the at least two zones being separated in a longitudinal direction of the mattress. 
Krevet sukladno zahtjevu 1 ili 2, naznačen time da se zona (21) koja ima čvrstoću koja se može podesiti proteže u osnovi duž cijele širine madraca (2), a zone su odvojene u uzdužnom smjeru madraca.
The composition comprises from 1 milligram (mg) to 20 mg of cladribine per unit dose, preferably from 2.5 mg to 15 mg, most preferably from 8 mg to 12 mg per unit dose. 
Pripravak, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što sadrži (a) od 8 mg do 12 mg po jediničnoj dozi, ili (b) 10 mg po jediničnoj dozi.
The mixture was pressed. 
Mješavina je isprešana.
A compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, as claimed in claim 15, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736, AZD1775 and AZD6738. 
Spoj s formulom (I) ili njegova farmaceutski prihvatljiva sol, za upotrebu za liječenje raka, prema zahtjevu 15, naznačen time da se spoj s formulom (D, ili njegova farmaceutski prihvatljiva sol primjenjuje u kombinaciji s najmanje jednom dodatnom protu-tumorskom tvari odabranom iz skupine koju čine cisplatin, oksaliplatin, karboplatin, valrubicin, idarubicin, doksorubicin, pirarubicin, irinotekan, topotekan, amrubicin, epirubicin, etopozid, mitomicin, bendamustin, klorambucil, ciklofosfamid, ifosfamid, karmustin, melfalan, bleomicin, olaparib, MEDI4736, AZD1775 1 AZD6738.
23, 24 and 25, wherein said antibody increases ITIM phosphorylation of FcYRIIB of Daudi cells about 4 to 10-fold in comparison to Daudi cells not treated with said antibody. 
23, 24125, gdje navedeno protutijelo povećava fosforiliranje ITIM u FcyRIIB kod Daudi stanica otprilike 4 do 10 puta u usporedbi s Daudi stanicama neobrađenim navedenim protutijelom.
T is absent or represents O, S, NR16 or CR16R17; represents optional bonds; 
T je odsutan ili predstavlja O, S, NR" ili CR"R'/;
The process according to any one of claims 1 to 4, wherein the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid has a molecular weight of less than 1 000 g/mol, preferably less than 750 g/mol and more preferably less than 500 g/mol. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da najmanje jedna u vodi topiva ne-polimerna organska i/ili anorganska slaba kiselina iili vodikova sol navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline ima molekularnu težinu od manje od 1000 g/mol, poželjno manje od 750 g/mol i još poželjnije manje od 500 g/mol.
In a further aspect, the invention relates to the compound of Formula I for use in therapy. 
U drugom aspektu, ovaj izum se odnosi na spoj s formulom I za uporabu u terapiji.
Iota-carrageenan for use as claimed in any one of claims 1 to 12, wherein the composition further comprises a non-carrageenan physiologically active compound, said compound optionally as the main active ingredient. 
Jota-karagenan namijenjen upotrebi u skladu s bilo kojim od patentni zahtjeva 1 do 12, naznačen time što pripravak dodatno sadrži fiziološki aktivan spoj koji nije karagenan, gdje navedeni spoj izborno može biti osnovni aktivni sastojak,
Further the aqueous pharmaceutical formulation also can comprise zinc, m-cresol, glycerol, polysorbate 20 and sodium and mixtures thereof in the ranges disclosed herein in relation to the aqueous pharmaceutical formulation of the present invention. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 18, naznačena time što navedeni farmaceutski pripravak dodatno sadrži pomoćne tvari, koje se bira iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
a light chain variable region CDR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 23-28; and 
(d) varijabilno područje slabog lanca CDR1 aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO:23 do SEQ ID NO:28; 1
Protein AA424839_P5 (SEQ ID NO:21) according to the present invention has an amino acid sequence as encoded by transcript AA424839_T2 (SEQ ID NO:18). 
Farmaceutski pripravak naznačen time da sadrži barem jedan CIORF32 polipeptid ektodomene odabran iz skupine koja sadrži: i. -C10RF32 polipeptid ektodomene koji sadrži sekvencu amino kiseline iz SEQ ID NO: 299; ii.
A sealed container according to any of claims 11 to 13, wherein the lidding film is a multi-layer film comprising a seal layer and the seal layer comprises polypropylene (PP) and/or PE. 
Cc) pružanje višeslojnog tankog filma koji sadrži sloj za pričvršćivanje i sloj za pričvršćivanje sadrži polipropilen (PP) i/ili PE.
a compound wherein R1 is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group or a hexyl group, 
R2 R3 y U naznačen time što R' predstavlja atom vodika, metil skupinu, etil skupinu, izopropil skupinu ili heksil skupinu,
Figure 6, 7 and 8 depict pharmacokinetic profiles of selected rapamycin carbohydrate derivatives in rats. 
Slike 6, 7 i 8 prikazuju farmakokinetske profile izabranih ugljikohidratnih derivata rapamicina u štakora.
a junction member slideably arranged in the body for movement in a longitudinal axis of the body to release a dose of a substance from a substance source, the junction member comprising a socket for receiving a spout of a substance source; 
element za povezivanje (41) koji je klizno razmješten u tijelu za kretanje u pravcu longitudinalne osi tijela da bi otpustio dozu supstance iz izvora supstance, pri čemu element za povezivanje sadrži čašicu (43) za prijem pipka (S) iz izvora supstance;
that a distributor plate at one of its sides is brought into contact with the dosing pistons wherein the distributor plate is brought into contact with two or more hydraulic piston at its other side for displacing the distributor plate for actuating the dosing pistons. 
- - ovođenje raspodjelno ploče na jednoj njenoj strani u doticaj s dozirnim kipovima, naznačen time sto raspodjelna ploča na svojoj drugoj strani dolazi u doticaj sa dva ili više hidraulička klipa koji pomiču raspodjelnu ploču radi aktivacije dozirnih klipova, 15.
The dietary supplement according to claim 5, wherein Cnidium Monnieri ranges from 50 mg to 300 mg per dosage unit. 
Nadomjestak prema patentnom zahtjevu 5, naznačen time da je Cnidium Monnieri u rasponu od 50 mg do 300 mg po jedinici doze.
expressing the nucleic acids of steps (a) and (b); wherein the secretion rate of the recombinantly expressed VKD protein is substantially increased when compared to the expression of the rVKD protein in a host organism which does not co-express rVKORC1. 
(c - ksprimiranje nukleinskih kiselina iz koraka (a) 1 (b); pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domačina, koji ne ko-eksprimira TVKORC1.
In one embodiment one or more R2 represents CH3O— or fluoro. 
(ili) predstavlja C'* alkiloksi ili fluoro .
X is H, or F; wherein each occurrence of X in a single molecule is independently defined; 
X je H, ili F; pri čemu je svaka pojava X u pojedinačnoj molekuli neovisno definirana;
(WO 02/100813) discloses compounds of PPAR modulators that are useful for treating type II diabetes and other PPAR-mediated diseases and conditions. 
(WO 02/100813) otkrivaju spojeve koji su modulatori PPAR, korisni u liječenju dijabetesa tip II i drugih bolesti i stanja posredovanih PPAR-ima.
The Wave-generating apparatus (1), according to claim 12, wherein the tongue (11) comprises a permeable strip (21) with an adjustable surface. 
Uređaj za generiranje valova (1), sukladno zahtjevu 12, pri čemu jezičac (11) obuhvaća propusnu traku (21) s prilagodljivom površinom.
arranging the first web and the second web to provide a series of parallel individual pockets (1711, 1712) having a hexagonal cross section; characterised in that the process further comprises providing one or more further webs (173) having a series of parallel grooves with a three-sided polygonal cross section and arranging the one or more further webs with the first web or the second web to provide a further series of individual pockets. 
(ili) postavljanje prve mreže i druge mreže na takav način da se oblikuje niz paralelnih pojedinačnih džepova (1711, 1712) šesterokutnog poprečnog presjeka; naznačen time, što postupak dalje podrazumijeva osiguravanje jedne ili više dodatnih mreža (173) s nizom paralelnih žljebova s poligonalnim trostranim poprečnim presjekom i raspoređivanje jedne ili više dodatnih mreža u položaj s prvom mrežom ili drugom mrežom kako bi se oblikovao dodatni niz pojedinačnih džepova.
1, the liquefied gas treatment system 100 according to the present embodiment includes a fuel supply line 110 and a BOG line 140 . 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor (150;13) sadrži više kompresijskih cilindara (14).
the heavy chain complementary determining region 1 (HCDR1) includes the amino acid sequence of SEQ ID NO: 2297, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2298 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2299, and the light chain complementarity determining region 1 (LCDR1) includes the amino acid sequence of SEQ ID NO: 2300, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2301 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2302; 
HCDR1 regije za određivanje komplementarnosti teškog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2297, HCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2298 i HCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2299 i LCDR1 regije za određivanje komplementarnosti lakog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2300, LCDR2 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2301 i LCDR3 koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2302; i
or R4 and R4' together with the nitrogen atom to which they are attached, form a 4-7 membered, saturated or partially saturated monocyclic heterocyclic ring, optionally containing a further heteroatom selected from N, O or S, and wherein said heterocyclic ring is optionally substituted with aryl, aryl-oxy-, C1-C7-alkyl, halo-C1-C7-alkyl or C1-C7-alkoxy, and said aryl is optionally substituted with halogen, C1-C7-alkyl, halo-C1-C7-alkyl or C1-C7-alkoxy. 
ili R4i R4' zajedno s dušikovim atomom na kojega su priključeni, tvore -člani do 7-člani, zasićeni ili djelomično zasićeni monociklički heterociklički prsten koji opcijski sadrži dodatni heteroatom odabran od N, O ili S, i pri čemu je navedeni heterociklički prsten opcijski supstituiran s arilom, aril-oksi-, C1-C7-alkilom, halo-C1-C7-alkilom ili C1-C7-alkoksi, i navedeni aril je opcijski supstiuiran s halogenom, C1-C7-alkilom, halo-C1-C7-alkilom ili C1-C7-alkoksi;
A pharmaceutical composition according to claim 1 or 2, wherein said arginine is free arginine. 
Farmaccutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni arginin.
a second component, being a composition, optionally presented in two or more parts for the preparation of a second colon cleansing solution by admixture with water, the second composition being a composition as claimed in any one of claims 1 to 11. 
B) drugu komponentu, koja je pripravak, izborno prisutan u dva ili više dijelova namijenjenih pripravi druge otopine za čišćenje debelog crijeva dodavanjem vode, gdje je drugi pripravak pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
An isolated nucleic acid encoding the mutated PE of any one of claims 1-8. 
Izolirana nukleinska kiselina koja kodira mutirani PE iz bilo kojeg od zahtjeva 1 do 5.
is an alkyl group, an olefinic group, or an aromatic group; 
R; je alkil skupina, olefin skupina ili aromatska skupina;
A solid dosage form comprising (A) particles consisting of amorphous bardoxolone methyl and a glass-forming excipient admixed with (B) particles consisting of hydroxypropyl methyl cellulose, wherein said particles (A) constitute a therapeutically effective amount of bardoxolone methyl. 
PATENTNI ZAHTJEVI Čvrsti oblik doziranja koji sadrži (A) čestice koje se sastoje od amorfnog bardoksolon metila i staklaste pomoćne tvari, gdje je oblik doziranja naznačen time što ima jednu temperaturu staklenja, u smjesi s
debenzylation of the compound of formula 7 to yield the compound of formula 8; wherein step (e) and step (f) are conducted in the same reaction mixture without isolation of the intermediate from step (e). 
(f)_debenzilacije spoja formule 7 kako bi se dobio spoj formule 8; pri čemu se korak (e) 1 korak (f) izvode u istoj reakcijskoj smjesi bez izdvajanja intermedijera iz koraka (e).
A microfluidic passive device and method for determining clotting time are described, of a fluid medium such as blood, of low production cost which can therefore be disposable. 
Mikrofluidički uređaj određivanja vremena koagulacije u fluidnom mediju, poput krvi ili plazme, gdje se navedeni uređaj sastoji od-
three heavy chain polypeptide CDRs depicted in SEQ ID NOs: 4, 9, and 14, respectively, or in their conservative sequence variants, and three light chain polypeptide CDRs depicted in SEQ ID NOs: 27, 32, and 37, respectively, or in their conservative sequence variants; 
tri CDRa teških lanaca polipeptida prikazanih u SEQ ID NOs: 4, 9 i 14, respektivno, te tri CDRa lakih lanaca polipeptida prikazanih u SEQ ID NOs: 27, 32 i 37, respektivno;
IC50 is determined from an inhibition response curve, logit-log plot of% B/Bo vs concentration of test compound. 
ICs, je određen iz krivulje inhibicije odgovora, logit-1og plot % B/Bo vs koncentracija test spoja.
Process according to claim 1, wherein a gas flow is released from the top of the first reactor section and the top of the second reactor section and combined and the combined gas flow of the both reactor sections is sent to a medium-pressure scrubber or a high-pressure scrubber, wherein ammonia and carbon dioxide present in the combined gas flow are removed from the gas flow by absorption in a low-pressure carbamate stream. 
Postupak prema zahtjevu 1, naznačen time što se protok plina oslobađa od vrha prvaog reaktorskog dijela i od vrha drugog reaktorskog dijela, a kombinirani protok plina oba odjeljka reaktora šalje sredstvima za gašenje srednjeg tlaka ili sredstvima za gašenje visokog tlaka, pri čemu se amonijak i ugljični dioksid prisutni u kombiniranom protoku plina uklanjaju iz protoka plina apsorpcijom u struji karbamata niskog tlaka.
The method of claim 18, wherein the helminth is Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia curticei, Nematodirus battus and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 15, naznačen time, da helmint je Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus axei, Trichostrongylus colubriformis, Cooperia curticei, Nematodirus battus i njihove kombinacije.
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37? C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
a frequency assignment setting section that sets a frequency assignment unit based on the number of clusters to apply to a terminal to which frequency is assigned; and 
planifikator (113) prilagođen dodjeljivanju resursa frekvencije terminalnom uređaju (400) na temelju veličine skupine blokova resursa koju postavlja sekcija postavljanja dodjele frekvencije (301);
The composition according to any one of claims 1 or 2, characterized in that the hedgehog shaped particles are composed of a material selected from the group comprising calcium carbonate containing material, especially precipitated calcium carbonate, natural calcium carbonate containing material, satin white, and mixtures thereof. 
Pripravak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da je materijal koji sadrži kalcijev karbonat odabran od istaloženog kalcijevog karbonata, prirodnog materijala koji sadrži kalcijev karbonat i njihovih smjesa.
The lipid particle of claim 7 or claim 8, wherein the particle further comprises a conjugated lipid that inhibits aggregation of particles, preferably wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate, preferably wherein the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof. 
Čestica lipida u skladu s patentnim zahtjevom 5 ili zahtjevom 6, naznačena time, da čestica nadalje sadrži konjugirani lipid koji inhibira agregaciju čestica, poželjno sadrži polietilenglikol (PEG) -lipid konjugat, pri čemu PEG-lipidni konjugat poželjno sadrži PEG-dijacilglicerol (PEG-DAG) konjugat, PEG-dialkiloksipropil (PEG-DAA) konjugat ili njihovu smjesu.
Method according to claim 1, wherein the catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicates, acidic ion exchange resins, carbon treated with HCl, H2SO4 or HNO3, and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je katalizator (N-kat.) odabran iz skupine koja se sastoji od octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, p-toluolsulfonske kiseline, HCI, HBr, H2SO4, HaPO4, BCLb, BF:0Et, MgCl, MgBr,, AICI;, ZnCL, Cu(BF;),, aluminosilikata, kiselih smola ionskih izmjenjivača sa HCI, H2SO, ili HNO; tretiranim ugljikom i njihovih mješavina.
a postprandial plasma glucose equal to or greater than 140 mg/dL; 
(b) reaktivna glukoza u plazmi je jednaka 1li veća od 140 mg/dI;
hydroxyl-; alkoxycarbonylamino-; as well as its enantiomers, diastereomers, mixtures thereof and pharmaceutically acceptable salts, tautomers, hydrates and solvates. 
HR P20150673 T1 o halogen-; o hidroksil-; o - alkoksikarbonilamino-; kao i njihovi enantiomeri, diastereomeri, njihove smjese i farmaceutski prihvatljive soli, tautomeri, hidrati i solvati.
protonating the dissolved free base with hydrochloric acid and maintaining the dissolved protonated free base at a temperature above 40°C for at least two hours; and allowing crystalline form II to form by cooling the dissolved protonated free base (e.g., at a temperature below 15°C). 
protoniranje slobodne baze sa klorovodičnom kiselinom i održavanje otopljene protonirane slobodne baze pri temperaturi iznad 40°C kroz barem dva sata; te dopuštanje da se stvori kristalni oblik II hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 15°C).
For achieving appropriate dissolution rate or bioavailability of nebivolol hydrochloride, micronized nebivoiol is needed. 
Za postizanje odgovarajuće stope otapanja ili biodostupnosti nebivolol hidroklorida, potreban je mikroniziran nebivolol.
The composition according to claim 4, wherein the (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, cholesterol, DSPC, and PEG-DMG have a molar ratio of 50:30:10:2 respectively. 
Pripravak u skladu s patentnim zahijevom 4, naznačen time, da je molarni omjer (13Z, 162)-N,N-dimetil-3-nonildocoza-13,16-dien-1-amin, kolesterol, DSPC i PEG-DMG 50:30:10:2.
The compound for use according to embodiment 11, wherein the disease is ankylosing spondylitis. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest ankilozirajući spondilitis.
The pharmaceutical composition of any one of claims 1 to 12 characterized in that the composition is a cream, comprising an oil phase and a water phase in admixture, the composition comprising about 4.5 to about 5.5 percent of the compound selected from the group consisting of imiquimod, sotirimod and resiquimod, about 20 to about 30 percent isostearic acid, about 1.0 percent to about 2.1 percent benzyl alcohol, about 0.5 percent to about 2.5 percent cetyl alcohol, about 1 percent to about 3.5 percent stearyl alcohol, about 2 percent to about 4 percent petrolatum, about 3 percent to about 4 percent polysorbate 60, about 0.4 percent to about 0.8 percent of sorbitan monostearate, about 1 percent to about 3 percent of glycerin, about 0.18 to about 0.22 percent methylparaben, about 0.018 percent to about 0.022 percent propylparaben, about 0.0 to about 1.0 percent xanthan gum, and about 50 to about 55 percent purified water; all percentages being based upon the total weight of the composition. 
Farmaceutski pripravak iz bilo kojeg od patentnih zahtjeva 1 do 9, naznačen time, da je taj pripravak krema koja sadrži uljnu fazu i vodenu fazu u smjesi, pripravak sadrži oko 4,5 do oko 5,5 posto spoja imikvimoda, oko 20 do oko 30 posto izostearinske kiseline, oko 1,0 posto do oko 2,1 posto benzil alkohola, oko 0,5 posto do oko 2,5 posto cetil alkohola, oko 1 posto do oko 3,5 posto stearil alkohola, oko 2 posto do oko 4 posto petrolatuma, oko 3 posto do oko 4 posto polisorbata 60, oko 0,4 posto do oko 0,8 posto sorbitan monostearata, oko 1 posto do oko 3 posto glicerina, oko 0,18 do oko 0,22 posto metilparabena, oko 0,018 posto do oko 0,022 posto propilparabena, oko 0,0 do oko 1,0 posto xanthan gume te oko 50 do oko 55 posto pročišćene vode; svi postotci temelje se na ukupnoj težini pripravka.
The method of claim 1, wherein the step of providing comprises providing at least about 1000 L of a culture. 
Postupak prema Zahtjevu 1, naznačen time, što korak osiguravanja sadrži osiguravanje najmanje oko 1000 L kulture.
The compound or pharmaceutically acceptable salt for use according to claim 9, wherein the disease is diastolic dysfunction. 
Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 9, pri čemu je bolest dijastolička disfunkcija.